Indoco Remedies Ltd Share Price – NSE /  BSE

Pharmaceuticals, Small Cap

The approval allows the company to market a generic version of Briviact 10 mg/mL oral solution, the reference listed drug (RLD) of UCB, Inc.

The company said its Brivaracetam Oral Solution has been determined to be bioequivalent and therapeutically equivalent to the RLD.

The product will be manufactured at Indoco Remedies? facility located at L-14, Verna Industrial Area, Verna, Goa ? 403722, India.

Brivaracetam Oral Solution (10 mg/mL) is a prescription antiepileptic drug indicated for the treatment of partial-onset seizures in patients aged one month and older.

Aditi Panandikar, managing director (MD) said, ?The ANDA approval for Brivaracetam is a significant milestone for us as we continue to strengthen our presence in the Regulated Markets. We are committed to offering innovative and affordable healthcare to patients worldwide.?

Indoco Remedies is engaged in the manufacturing and marketing of Formulations and Active Pharmaceutical Ingredients. The Company caters to both Domestic and International markets.

The company?s consolidated net loss of Rs 23.64 crore in Q3 FY26 as against net loss of Rs 27.30 crore in Q3 FY25. Revenue from operations rose 7.9% year on year to Rs 434.34 crore in Q3 FY26.

Powered by Capital Market - Live News

Net Loss of Indoco Remedies reported to Rs 29.79 crore in the quarter ended December 2025 as against net loss of Rs 26.39 crore during the previous quarter ended December 2024. Sales rose 7.92% to Rs 434.34 crore in the quarter ended December 2025 as against Rs 402.45 crore during the previous quarter ended December 2024.

Powered by Capital Market - Live News

Indoco Remedies has allotted 55,700 equity shares under ESOP on 03 February 2026. Consequent to this allotment, the paid up equity share capital has increased to Rs. 18,46,07,210 (consisting of 9,23,03,605 equity shares of face value of Rs. 2 each).

Powered by Capital Market - Live News

Indoco Remedies announced final approval of the Company's Abbreviated New Drug Application (ANDA) for Lacosamide Oral Solution USP, 10 mg/mL, to market, a generic equivalent to the reference listed drug (RLD), Vimpat Oral Solution, 10 mg/mL, of UCB, Inc. (UCB), from USFDA.

Lacosamide Oral Solution USP, 10 mg/mL, is bioequivalent and therapeutically equivalent to the reference listed drug, Vimpat Oral Solution, 10 mg/mL, of UCB, Inc. (UCB).

Lacosamide Oral Solution USP, will be manufactured by Indoco Remedies, at their manufacturing facility located at L-14, Verna Industrial Area, Verna, Goa ? 403722 in India.

Lacosamide Oral solution is used to treat partial onset seizures and primary generalized tonic-clonic seizures in adults and children with epilepsy who are at least 4 years old.

Powered by Capital Market - Live News